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Abstract 
Background. Biodefense vaccines against Category B bioterror agents Burkholderia pseudomallei (BPM) 
and Burkholderia mallei (BM) are needed, as they are both easily accessible to terrorists and have strong 
weaponization potential. Burkholderia cepaciae (BC), a related pathogen, causes chronic lung infections in 
cystic fibrosis patients. Since BPM, BM and BC are all intracellular bacteria, they are excellent targets for T 
cell-based vaccines. However, the sheer volume of available genomic data requires the aid of immunoinfor-
matics for vaccine design. Using EpiMatrix, ClustiMer and EpiAssembler, a set of immunoinformatic vac-
cine design tools, we screened the 31 available Burkholderia genomes and performed initial tests of our 
selections that are candidates for an epitope-based multi-pathogen vaccine against Burkholderia species.  
Results. Immunoinformatics analysis of 31 Burkholderia genomes yielded 350,004 9-mer candidate  
vaccine peptides of which 133,469 had perfect conservation across the 10 BM genomes, 175,722 had per-
fect conservation across the 11 BPM genomes and 40,813 had perfect conservation across the 10 BC ge-
nomes. Further screening with EpiMatrix yielded 54,010 high-scoring Class II epitopes; these were assem-
bled into 2,880 longer highly conserved ‘immunogenic consensus sequence’ T helper epitopes. 100% of 
the peptides bound to at least one HLA class II allele in vitro, 92.7% bound to at least two alleles, 82.9% to 
three, and 75.6% of the binding results were consistent with the immunoinformatics analysis.  
Conclusions. Our results show it is possible to rapidly identify promiscuous T helper epitopes conserved 
across multiple Burkholderia species and test their binding to HLA ligands in vitro. The next step in our 
process will be to test the epitopes ex vivo using peripheral leukocytes from BC, BPM infected humans and 
for immunogenicity in human HLA transgenic mice. We expect that this approach will lead to development 
of a licensable, pan-Burkholderia biodefense vaccine. 
Background 
 
Due to their exceptionally high virulence in animals and 
humans, and their potential for weaponization as aero-
sols, BP and BPM are both classified as category B bio-
threat agents. In addition to use as a countermeasure, 
Burkholderia vaccines would also contribute to improv-
ing human health in certain patient populations (such as 
immunocompromised patients) and sectors of the globe 
(such as Thailand) most affected by exposure to these 
pathogens.  
Attempts to develop both whole-cell killed and live at-
tenuated vaccines against Burkholderia species, have 
failed to result in a complete protective immune re-
sponse in mice. Ulrich et al. developed two differently 
attenuated strains of B. mallei (a capsule-negative mu-
tant and a branched-chain amino acid auxotroph) to 
protect against aerosolized B. mallei challenge. No  
 
 
protection was observed to the capsule-negative mutant, 
but the auxotroph conferred a slight protective advantage 
although the mice did not clear the infection [1]. Other 
vaccine targets include the capsular polysaccharides and 
LPS, as there is significant genetic and structural 
conservation between the capsular polysaccharides of 
these species [2]. Recently, subunit vaccines against BC 
have shown promise. Mice nasally immunized with 
Burkholderia multivorans outer membrane proteins rap-
idly resolved pulmonary infections following B. mul-
tivorans challenge and also elicited cross-protection 
against B. cenocepacia [3, 4]. Although B. cepaciae pro-
teins that appear to be protective have been identified, no 
vaccine against BC currently exists [5]. To date, no 
vaccine for any pathogenic Burkholderia species is ap-
proved for human use. 
Although antibodies can protect against severe infection 
by BM, passive prophylaxis has not been shown to con-
fer sterilizing protective immunity. This is likely due to 
Burkholderia’s capability of latent long-term intracellu-
lar infections. Cell-mediated immune response, in con-
junction with a humoral response, may be required to 
successfully protect against infection with Burkholderia 
species, and to clear intracellular infections. In general, 
it is believed that robust cell-mediated immune          
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responses to Burkholderia will be required for an effec-
tive protective or therapeutic vaccine [6].  
Evidence for protective cellular immune response to 
BPM infection comes from several live attenuated vac-
cine studies in mice and suggests that cell-mediated im-
munity is critical. Immunization of C57BL/6 mice with a 
mutant of BPM (aroC) deficient in aromatic amino acid 
synthesis resulted in sterile immunity [7]. BALB/c mice 
inoculated with a BPM transposable 2D2 insertion 
mutant (ilvl) auxotrophic for branched chain amino acids 
induced a protective response and 85% survived a lethal 
wild type BPM challenge. However, BPM persisted in 
spleen, liver, kidney and lung tissues up to 30 days post 
challenge [8]. Splenic BPM-specific T cells, detected in 
immunized mice, proliferated and produced interferon-
gamma in vitro in response to dead bacteria. Assessment 
of T cell antigen specificity indicated that subpopulations 
of BPM-specific T cells were responsive to secreted pro-
teins. Adoptive immunization of severe combined immu-
nodeficiency mice with T cells from 2D2 live-attenuated 
BPM mutant-immunized mice resulted in increased sur-
vival compared to naïve T cell recipients. This suggests 
that 2D2 immunization can generate T cell-mediated 
immunity [9]. CD4+ and CD8+ cell depletion studies 
argue that CD4+ cells, but not CD8+ cells, mediated this 
protection in vivo.  
Cell mediated immune response to antigens produced by 
live organisms are important to protection from 
Burkholderia. In a separate study, immune responses and 
resistance following subcutaneous immunization with 
live BPM were compared with exposure to heat-killed 
culture filtrate and sonicated BPM antigens. Compared to 
heat-killed BPM, significant protection was generated in 
BALB/c mice following exposure to live bacteria. Thus, 
CD4+ T cells can mediate vaccine-induced immunity to 
experimental melioidosis [9]. These studies suggest 
CD4+ T cell recognition of processed and secreted pro-
teins from live bacteria are crucial for disease protection. 
These results also suggest that the type of immune re-
sponse generated in vivo is influenced by the nature of 
the BPM antigens, and that immune responses to those 
proteins that are actively secreted may be required to 
stimulate a protective immune response [10]. 
T cell epitopes are critical mediators of cellular immunity 
and are derived from a pathogen„s proteins via two path-
ways. In one, a protein derived from an intracellular 
pathogen is processed and its constituent peptides bind to 
major histocompatability complex (MHC) Class I mole-
cules. Alternatively, proteins derived from pathogens 
external to the antigen presenting cells (APCs) are proc-
essed in the proteolytic compartment; these constituent 
peptides bind to MHC Class II molecules. After process-
ing and binding, MHC Class I and Class II peptide com-
plexes are then transported to the surface of an APC, 
where they are exposed to interrogation by passing T 
cells (CD8+ and CD4+ T cells, respectively). From these 
different antigen processing and presentation pathways, 
two different T cell responses are generated: a CD4+ T 
helper immune response and a CD8+ cytotoxic lympho-
cyte immune response. After initial exposure to pathogen 
(or vaccine), memory T cells are established that respond 
more rapidly and efficiently upon subsequent exposure. 
We have previously used this genome-derived epitope-
based vaccine design approach to develop a prototype 
Francisella tularensis Type A (subsp. tularensis) vaccine 
that confers 60% protection against heterologous lethal 
respiratory challenge with the live vaccine strain (LVS), 
an attenuated subsp. holarctica derivative [11, 12]. To 
our knowledge no subunit vaccine for tularemia has 
achieved a comparable level of protection in this well-
developed lethal respiratory challenge model in HLA 
transgenic mice. In parallel studies, we developed an 
epitope-based vaccine composed of T cell epitopes de-
rived from sequences conserved between vaccinia and 
variola. This vaccine was 100% protective against intra-
nasal small pox challenge in HLA transgenic mice and 
occurred in the absence of detectable antibody response 
[13]. Seven poxvirus genomes were previously the 
maximum number submitted for analysis by our vaccine 
design tools. Here we employed the same approach to a 
much larger set of genomic sequences, with the goal of 
selecting the optimal sequences for a vaccine that could 
protect against multiple Burkholderia species.   
 
Methods 
We utilized bioinformatics and immunological tools to 
identify candidate proteins from 31 Burkholderia ge-
nomes for inclusion in a multipathogen-specific prophy-
lactic vaccine as previously published [11, 13, 14]. De-
tails on the approach used for the multipath vaccine are 
provided below. We then used T cell epitope mapping 
tools (Conservatrix, EpiMatrix) to identify 9-mer amino 
acid sequences that were both highly conserved in 
Burkholderia genomes and potentially immunogenic. 
These putative epitopes were then assembled into immu-
nogenic consensus sequence clusters (using EpiAssem-
bler) and their in vitro binding properties tested against 5 
human class II HLA alleles. We then hand-selected the 
best 70 clusters, of which 41 were synthesized for further 
testing in soluble HLA binding assays as previously de-
scribed [11, 13]. 
 
Genome Collection 
Genomes from 31 strains of Burkholderia were obtained 
from Pathema, a proprietary genome database from the J. 
Craig Venter Institute (http://pathema.jcvi.org/cgi-bin/
Burkholderia). These included protein-coding genomes 
from 10 B. mallei strains (FMH: 5600 ORFS; 
NCTC10229: 5519 ORFS; 2002721280: 5519 ORFS; 
ATCC10399: 5746 ORFS; ATCC23344: 5229 ORFS; 
GB8: 5936 ORFS; JHU: 5559 ORFS; NCTC10247: 5869 
ORFS; PRL-20: 5469 ORFS; and SAVP1: 5200 ORFS), 
11 B. pseudomallei strains (1106a: 7180 ORFS; 1106b: 
7223 ORFS; 1655: 6908 ORFS; 1710a: 7540 ORFS; 
406e: 6866 ORFS; 576: 7400 ORFS; 668: 7135 ORFS; 
K96243: 6304 ORFS; MSHR346: 7588 ORFS; PAS-
TEUR52237: 7140 ORFS; S13: 7253 ORFS), 2 B. ambi-
faria strains (AMMD: 6976 ORFS; MC40-6: 7163 
ORFS), 2 B. cenocepacia strains (AU1054: 7109 ORFS; 
HI2424: 7227 ORFS), 5 B. multivorans strains 
(ATCC17616-JGI: 6779 ORFS; ATCC17616-Tohoku: 
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6699 ORFS; CGD1: 6572 ORFS; CGD2: 6653 ORFS; 
CGD2M: 6646 ORFS) and 1 B. vietnamiensis strain. B. 
ambifaria, B. cenocepacia, B. multivorans and B. viet-
namiensis (G4: 8423 ORFS)  comprise the Burkholderia 
cepaciae complex group [15]. 
 
Genome Alignment and Cross-walk 
In order to identify proteins conserved within various 
Burkholderia species, the B. mallei, B. pseudomallei and 
B. cepaciae strains were aligned using GB8, MSHR346 
and G4 as reference genomes, respectively. These intra 
species conserved proteins were then analyzed for inter-
species conservation using a comparative genomics tool 
from Pathema (http://pathways.jcvi.org/comp-genomics). 
This identified proteins in each of the three reference 
genomes that have hits (defined as any two proteins with 
a sequence identity greater than or equal to 80%) among 
the selected comparison genomes. 
 
Secretion Analysis and Conservatrix 
The Phobius program was used to identify single pep-
tides and transmembrane segments and the LipoP pro-
gram was used to identify lipoprotein attachment sites in 
proteins from each of the 31 Burkholderia genomes 
(http://phobius.sbc.su.se/; http://www.cbs.dtu.dk/
services/LipoP/) [16, 17].  Proteins with a signal 
sequence, no lipoprotein attachment sites and no more 
than 1 transmembrane segment were selected for further 
analysis (Figure 1). In order to target functionally or 
structurally important epitopes that are conserved be-
tween Burkholderia species, the Conservatrix algorithm 
parsed input sequences into component strings, typically 
comprised of overlapping 9-mer segments, then searched 
the input database for matching segments found in at 
least two of the three Burkholderia species and ultimately 
produced a sequence conservation frequency table for 
each 9-mer.  
 
EpiMatrix Analysis 
EpiMatrix, a matrix-based epitope-mapping algorithm, 
was used to identify Class II HLA epitopes from the con-
served 9-mer peptides identified. Potential binding of the 
9-mer sequences was scored for 8 common HLA alleles 
that cover >90% of the human population (DRB1*0101, 
DRB1*0301, DRB1*0401, DRB1*0701, DRB1*0801, 
DRB1*1101, DRB1*1301 and DRB1*1501) [18, 19]. 
While assessment scores (Z-scores) range from 
approximately -3 to +3, Z-scores equal to or greater than 
1.64 are generally comprise the top 5% of any given 
peptide set, are defined as “Hits” and considered poten-
tially immunogenic. Z-scores above 2.32 are in the top 
1% and are extremely likely to bind MHC molecule. A 9-
mer frame predicted to react to at least 4 different HLA 
alleles is considered an EpiBar. EpiBars may be the sig-
nature feature of highly immunogenic, promiscuous class 
Figure 1: Selection of conserved and secreted Burkholderia proteins. Proteins containing a signal sequence, lacking lipoprotein attachment sites and lacking predicted 
transmembrane domains were analyzed for conservation across 3 Burkholderia reference genomes (B. mallei GB8, B. pseudomallei MSHR346 and B. cepaciae G4). 
Figure 2: EpiBar located on peptide MP-ICS-CLUSTERS-31-02A. EpiMatrix analysis of the BPM amino ABC transporter, periplasmic amino acid-binding protein 
(GenBank ID# 237814370) identified residues 210-220 within the MP-ICS-CLUSTERS-31-02A peptide as an immunogenic EpiBar. High Z-scores (above 1.64) across 
4 or more human class II MHC alleles are considered hits and constitute an EpiBar.  
 De Groot et al. Immunome Research 2011, 7:2:7                 
http://www.immunome-research.net/          
         Page 4 of 10 
Figure 3: Constructing an Immunogenic Consensus Sequence. (A) EpiAssembler identified a core conserved 9-mer epitope (red) and identified naturally overlapping 
N- and C-terminal flanking regions from other 9-mer epitopes (orange, green and blue) in a serial fashion to generate a composite immunogenic consensus sequence. 
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II epitopes (Figure 2); in previously published studies we 
have observed that these epitopes tend to be more immu-
nogenic than epitopes that do not contain EpiBars [11-
13]. 
 
EpiAssembler and Blastimer 
EpiAssembler was then used to identify sets of overlap-
ping and conserved epitopes from selected 9-mer pep-
tides, as well as assemble them into extended immuno-
genic consensus sequences (ICS) [20]. This algorithm 
iteratively identifies core highly conserved sequences 
that contain multiple putative T cell epitopes (clusters) 
and extends the core sequence right and left culling from 
a database of similarly highly conserved, putatively epi-
tope rich sequences (Figure 3). The EpiMatrix scores 
within these ICS clusters are then aggregated to create an 
EpiMatrix Cluster Immunogenicity Score. As cross-
reactivity with self may lead to deleterious immune re-
sponses, we evaluated the ICS clusters for homology to 
the human genome by BLAST analysis [21]. Peptides 
sharing greater than 70% identity with sequences in the 
human genome were eliminated from consideration.  
None of the 2,880 Burkholderia ICS clusters were found 
to have significant homology (>90%) to the human ge-
nome. 
 
ICS Selection and Peptide Synthesis 
In order to minimize technical difficulties with peptide 
synthesis and low water solubility stemming from hydro-
phobic peptides, the amino acid hydropathy score was 
assessed for each ICS cluster by GRAVY [22]. Each ICS 
sequence was constructed to contain a minimal set of T 
cell epitopes, as well as cover a maximum number of 
observed Burkholderia strains. This was accomplished 
by comparing the remaining ICS clusters for cross-
species conservation. Selected epitopes were synthesized, 
purified by HPLC and verified by mass spectrometry 
(21st Century Biochemicals, Marlboro, MA). 
Class II HLA binding assay 
Purified, soluble HLA Class II DR competition binding 
assays were performed as previously described [23]. 
Briefly, non-biotinylated ICS peptides over a wide range 
of concentrations competed with biotinylated influenza 
hemagglutinin 306-318 standard peptide (0.1 M) for 
binding to purified DRB1*0101, DRB1*0301, 
DRB1*0401, DRB1*0701, and DRB1*1501 (50 nM) in 
96-well plates for 24 hours at 37°C. ELISA plates coated 
with pan anti-Class II antibodies (L243, anti-HLA-DR; 
BioXCell, West Lebanon, NH) were blocked with 5% 
FBS in PBS-0.05% Tween-20 and then bound to the DR/
peptide complexes for 1 hour at 37°C. Following exten-
sive washing in PBS-0.05% Tween-20, the ELISA plates 
were developed by addition of streptavidin-europium and 
analyzed on a Victor3V Microtiter Plate Reader. Percent 
inhibition and IC50 values of the biotinylated peptide 
binding were calculated using SigmaPlot 11.1 software. 
 
Results  
In silico epitope mapping 
Conservatrix, EpiMatrix. Comparative genomic align-
ment analysis of the B. mallei GB8, B. pseudomallei 
MSHR346 and B. cepaciae G4 genomes as references 
yielded a total of 3,288 proteins conserved across all 10 
genomes of B. mallei, 4,682 proteins conserved across all 
11 genomes of B. pseudomallei and 2,823 proteins con-
served across all 10 genomes of B. cepaciae. LipoP and 
Phobius analyses identified 10,793 secreted core ORFs. 
Conservatrix analysis of these ORFs yielded 350,004 9-
mer peptides; of which 133,469 had perfect conservation 
across the 10 BM genomes, 175,722 had perfect conser-
vation across the 11 BPM genomes and 40,813 had per-
fect conservation across the 10 BC genomes. EpiMatrix 
analyses of these conserved Burkholderia 9-mer peptides 
yielded 54,010 putative Class II HLA epitopes. 
EpiAssembler. Using the 54,010 unique 9-mer peptides 
as a starting point, EpiAssembler produced 2,880 candi-
date ICS clusters. Figure 3 shows a conceptual example 
of ICS assembly from conserved and overlapping HLA 
peptide epitopes using EpiAssembler. 
Blastimer. Cross-conservation with the human genome 
may lead to deleterious anti-self immune responses to 
vaccines. Therefore, we used BLAST analysis to confirm 
that none of these ICS clusters had any significant ho-
mology to the human genome. GRAVY analysis re-
moved 19 ICS clusters with extremely hydrophobic prop-
erties. Cross-species conservation analysis yielded 90 
ICS epitopes >70% conserved between B. mallei and B. 
pseudomallei, 42 ICS clusters >70% conserved between 
B. mallei and B. cepaciae, 32 ICS clusters >70% con-
served between B. pseudomallei and B. cepaciae and 20 
ICS clusters >70% conserved among all 3 Burkholderia 
species.  
Protein ontology. The top-scoring 70 Class II ICS clus-
ters were selected for further analysis (Table 1). These 
ICS cluster peptides indeed correspond to Burkholderia 
proteins predicted to have a variety of cellular functions 
(Figure 4). Many of these proteins, such as                
 
 
 
Figure 4: Functional classification of identified 
immunogenic consensus sequence cluster source 
proteins. Functional categories are based on cellular 
biological processes ascertained from manual gene 
ontology analysis using the UniProt protein database.  
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Table 1: Class II Epitopes selected for HLA-binding analyses. Column 1: Immunogenic consensus sequence peptide cluster ID; column 2: amino acid 
sequence for each peptide; column 3: protein description for the parent protein from GenBank; columns 4-6: GenBank ID reference numbers for the 
reference genomes B. mallei (BM) GB8, B. pseudomallei (BPM) MSHR346 and B. cepaciae (BC) G4. 
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transmembrane transporters, transmembrane and ex-
tracellular receptors, cell wall and membrane biogenesis 
proteins and flagellar proteins, are predicted to function 
at the bacterial cell surface, even though they passed the 
initial screen for putative secreted proteins. In at least 
four cases, transcription factors have been identified as 
secreted proteins [24-28], thus while rare, this is not an 
unprecedented observation. Based on the previous exam-
ples, secretion of these proteins may be indicative of a 
highly immunogenic protein, therefore we have elected 
to retain these epitopes in our vaccine development pro-
gram.  
BLAST against other bacterial proteins. A BLAST 
search was performed for the epitopes identified in this 
manner against non-human, bactetrial protein. No hits 
were identified that had greater than 70% conservation 
(six out of nine amino acid residues conserved). There-
fore, these epitopes are relatively unique and unlikely to 
be cross reactive with other commensals and other patho-
gens. Vaccination with these epitopes would be expected 
to drive a pan-Burkholderia immune response; that will 
be the focus of the next stage of our gene-to-vaccine pro-
gram. 
 
Class II HLA-binding analyses 
Peptide binding affinities for HLA DRB*0101, 
DRB1*0301, DRB1*0401, DRB1*0701, and 
DRB1*1501 were determined in competitive binding 
assays. Of the 205 ICS peptide-HLA binding interactions 
assayed, 44% displayed strong binding (IC50<10), 30% 
showed moderate binding (10<IC50<100) and 22% dis-
played weak or non-binding (IC50>100). In only 9 cases, 
the HLA binding results were inconclusive (Figure 5).  
All peptides bound to at least one of the HLA alleles for 
which they were predicted, 92.7% bound to two alleles 
for which they were predicted, 82.9% bound to three 
alleles for which they were predicted. These data support 
the use of this approach for the high-volume genomic 
screening for vaccine candidates. Therefore, we pro-
ceeded to the next step in our development process with 
this highly conserved, highly promiscuous candidate 
epitope cohort. 
Comparison between computational predictions and ac-
tual in vitro HLA binding results show 75.6% overall 
predictive success rate when excluding inconclusive re-
sults (Figure 6). Epitope prediction success was also 
compared for each class II MHC allele. Successful bind-
ing prediction was 76.3% for DRB1*0101, 59.5% for 
DRB1*0301, 82.9% for DRB1*0401, 78.6% for 
DRB1*0701 and 79.5% for DRB1*1501. A lack of ac-
cord between positive binding predictions and actual 
binding data was observed at 23.7% for DRB1*0101, 
40.5% for DRB1*0301, 17.1% for DRB1*0401, 9.5% 
for DRB1*0701 and 20.5% for DRB1*1501 (Figure 6). 
This could be due to the affinity of the competitor pep-
tide (bound too tightly to compete off), peptide synthesis, 
problems with peptide aggregation in the in vitro assay, 
or lack of predictive accuracy by the EpiMatrix tool. In a 
large, retrospective comparison of the EpiMatrix with 
other online tools, EpiMatrix was as accurate or more 
accurate than other available epitope prediction tools 
[29]. Therefore, it is likely that much of the discrepancy 
between predictions and HLA binding is due to physical 
interference in the in vitro assay.   
Figure 5: MHC Class II HLA-binding analysis for promiscuity. Col-
umn 1: Inter-Burkholderia species conservation of immunogenic consen-
sus sequence (ICS) peptides (B. mallei = BM, B. pseudomallei = BPM, B. 
cepaciae = BC); column 2: ICS peptide ID; columns 3-7: ICS peptide 
binding affinities to the human HLA class II alleles DRB1*0101, 
DRB1*0301 DRB1*0401 DRB1*0701 DRB1*1501. Weak or no affinity 
(IC50>100 M = white); moderate affinity (100 M >IC50>10 M = light 
blue); strong affinity (IC50<10 M = dark blue); inconclusive binding 
(hash). 
Figure 6: EpiMatrix binding prediction success. The HLA class II 
binding result for each ICS peptide was compared to its EpiMatrix predic-
tive binding scores for each human HLA class II allele. True positives 
(dark blue) reflect correctly predicted HLA-binding peptide results. False 
positives (medium blue) reflect incorrectly predicted HLA-binding peptide 
results. True negatives (light blue) reflect correctly predicted non-HLA-
binding peptide results. False negatives (grey) indicate incorrectly pre-
dicted non-HLA-binding peptide results.  
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Discussion 
Using publically accessible bioinformatics tools we iden-
tified secreted proteins conserved between 31 different 
Burkholderia genomes and used our validated vaccine 
design toolkit to select highly conserved class II epitope 
clusters as potential T cell epitopes for a T cell directed 
vaccine. These peptides were then evaluated for their in 
vitro binding properties to 5 different human class II 
HLA alleles.  
Burkholderia mallei (BM) and Burkholderia pseu-
domallei (BPM) are responsible for the severe diseases 
glanders and melioidosis, respectively. Burkholderia 
mallei is a Gram-negative, non-motile bacillus that re-
quires a mammalian host environment for survival 
(Whitlock et al., 2007). BM is the etiological agent of 
glanders in donkeys, mules, horses and occasionally hu-
mans. Horses are the predominant natural reservoir for 
BM and transmission to humans occurs through direct 
contact with infected animals [30].  While BM is gener-
ally confined to animal species, it can cause severe respi-
ratory infection when aerosolized and for that reason is 
considered, along with BPM, a Category B pathogen by 
the NIAID Biodefense Research Agenda [31].   
Burkholderia pseudomallei, the etiological agent of 
melioidosis, is a Gram-negative, facultatively anaerobic, 
motile bacillus that is responsible for a broad spectrum of 
illnesses in both humans and animals. The incidence of 
disease is particularly high in Southeast Asia. In Thai-
land, an estimated 20% of community-acquired septice-
mias and approximately 40% of deaths due to complica-
tions associated with bacterial sepsis can be attributed to 
this organism [32, 33]. Antibiotic therapy is the first line 
of defense post-exposure but faces significant challenges. 
Despite extensive antibiotic regimens, recurrence of in-
fection ranges from 13% to 26% and therapy choice is 
limited by antibiotic resistance [32, 34, 35]. As a result, 
mortality rates as high as 50% in northeast Thailand and 
~20% in Northern Australia have been observed [32, 34, 
36]. However, infection with this pathogen in tropical 
regions of the world may be underreported. 
Recrudescence may occur: reactivation of latent BPM in 
Vietnam veterans up to 18 years after their last exposure 
has been reported [37].  
Burkholderia cepaciae (BC) is a Gram-negative, non-
sporulating motile bacillus found in a variety of both 
aquatic and terrestrial environments [38]. BC is an 
opportunistic human pathogen associated with life-
t h r e a t e n i n g  p u l m o n a r y  i n f e c t i o n s  i n 
immunocompromised individuals and individuals with 
cystic fibrosis [39].  
Based on their highly infectious properties in aerosol 
form and extremely high virulence, BPM and BM are 
both classified as category B bioterrorist agents. There is 
currently no vaccine available for any Burkholderia spe-
cies. Due to the potential bioterrorism threat, the devel-
opment of a safe and effective Burkholderia vaccine is a 
national and worldwide goal. Addition of BC sequences 
may contribute to the development of a vaccine that 
could prevent disease in select cystic fibrosis patient 
populations in the United States. 
Conventional vaccines using whole killed, whole protein, 
or live attenuated have offered success for over a century. 
However, development of a Burkholderia vaccine 
through this approach has proven elusive. Inactivated 
whole cell vaccines provided some Burkholderia protec-
tion in mouse models, but protection in intravenously 
challenged mice and sterile immunity was unsuccessful 
[10, 40-42]. Furthermore, killed, whole-cell BM vaccines 
did not protect the vaccinated mice from a live challenge 
(>300 50% lethal doses), suggesting that proteins or 
polysaccharides that are produced by live bacteria are 
critically important to protection from BPM and BM dis-
ease [43]. BPM vaccine studies using live attenuated 
virus, killed virus and adoptive immunization provide 
evidence for CD4+ T cell-mediated vaccine-induced im-
munity to melioidosis [9]. Despite this progress in vac-
cine development, Burkholderia’s propensity for latent 
infections along with the undefined mechanistic nature 
behind several attenuated Burkholderia strains pose sig-
nificant challenges towards developing vaccines ap-
proved for human use. Contemporary immunome-
derived vaccines have a significant advantage over con-
ventional vaccines; the careful selection of the vaccine 
components through the use of computer-driven analysis 
should diminish undesired side effects as those observed 
with whole pathogen and protein subunit vaccines.  
This study couples the current boon of genomic resources 
with our sophisticated bioinformatics and immunoinfor-
matic tools to design candidate peptide epitopes for a 
multi-species Burkholderia vaccine. This approach 
moves away from whole protein, killed whole cell and 
attenuated pathogen-based Burkholderia vaccines for 
several reasons. Potentially dangerous cross-reactive or 
inert space-consuming epitopes present in canonical vac-
cines are not included in the vaccine. By eliminating su-
perfluous components, epitope-based vaccines maximize 
their immunogenic payload as well as maximize the pro-
tective efficacy to direct a broad based immune response 
against multiple antigenic proteins associated with the 
pathogen(s) and also reduce formulation challenges and 
cost. Safety concerns stemming from the use of intact 
recombinant proteins that may have undesired biological 
activities, such as enzymes, immunomodulators, cross-
reactivity or toxins, may also be mitigated through tar-
geted epitope approach. These bioinformatics sequence 
analysis tools, epitope-mapping tools, microarrays and 
high-throughput immunology assays successfully identi-
fied the minimal essential vaccine components for small-
pox, tularemia, Helicobacter pylori and tuberculosis vac-
cines [11-13]. As described here, we are also using this 
approach for the development of a vaccine for biodefense 
against multiple Burkholderia species. The tools enabling 
these vaccine development successes are described here, 
and the anticipated clinical development of immunome-
derived and epitope-driven vaccines will be the subject of 
future reports.  
Our results show it is possible to identify and in vitro 
validate T cell epitopes that are conserved across multi-
ple Burkholderia species. These epitopes will be further 
tested in human PBMC and transgenic mice. We aim to 
use these epitopes for inclusion and further testing in a 
multi-pathogen-specific Burkholderia vaccine. We antici-
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pate that a multi-epitope construct could be administered 
with an anti-LPS vaccine, already in clinical trial [44], 
resulting in an effective vaccine directed at providing 
both humoral and cellular immune response. The result-
ing multi-pathogen Burkholderia vaccine will benefit 
both the developing world and biodefense. 
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